Takeda Announces Positive Results for TYK279 to Treat Patients with Active Psoriatic Arthritis
Takeda presented encouraging results from the Phase 2b trial (NCT05153148) at the November 2023 American College of Rheumatology (ACR) convergence in San Diego. The Phase 2b study evaluated TYK279 which…